Infectious diseases kill nearly 10 million people a year; primarily in developing countries, where access to preventive care and treatment is limited. But even in the United States, new strains of disease emerge periodically, which must be addressed quickly and effectively.
Funded by the Bill & Melinda Gates Foundation, Grand Challenges in Global Health encompasses 43 project across 33 countries, working toward scientific breakthroughs to prevent, treat and cure diseases that kill millions each year.
Poor nutrition is linked to more than half of all child deaths worldwide. This initiative, funded by the Bill & Melinda Gates Foundation, draws together an international group of scientific investigators to study the inter-relationship between enteric infections and malnutrition to reduce its devastating effects.
The Foundation for the NIH's portfolio of HIV/AIDS research projects, all part of Gates Foundation's Collaboration for AIDS Vaccine Discovery, is working to expedite development of an effective AIDS vaccine.
The Swanson Family Fellowship supports research in TTF-1 Mutation Causing Benign Chorea in the laboratory of infectious diseases under the direction of Steven M. Holland, M.D., Chief of the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases at NIH.
The HIT-TB project is a collaboration between the FNIH and the National Institute of Allergy and Infectious Diseases, along with academic institutions in the United Kingdom and South Africa, and is supported by a grant from the Bill & Melinda Gates Foundation. Its focus is on combating tuberculosis, which infects one-third of the world’s population.
The “Vector-based Control of Transmission: Discovery Research” program is an extension of the Grand Challenges in Global Health initiative, aimed at establishing a pipeline of innovative new tools that will be safe, easily deployed, effective and sustainable for use in the control of mosquito-borne diseases. A 5-year $25 million grant was awarded to the FNIH in 2009 by the Bill & Melinda Gates Foundation. The program has subsequently been extended to 2016 with additional funding.
This project aims to address a fundamental problem blocking the development of a successful HIV-1 vaccine. The goal is to understand how best to design T cell immunogens to address the broad genetic diversity of HIV-1.